Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06825403 · ClinicalTrials.gov registry record · NA

Olfactory Training in Mild Cognitive Impairment

A NA study of Mild Cognitive Impairment, sponsored by Jeffrey Motter.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT06825403: Recruiting NA study of Mild Cognitive Impairment, sponsored by Jeffrey Motter.

NCT06825403 is a NA study of Mild Cognitive Impairment that is actively recruiting participants, run by Jeffrey Motter. The registered enrollment target is 30 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06825403, a NA study of Mild Cognitive Impairment, is actively recruiting participants, sponsored by Jeffrey Motter.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

Sense of smell tends to decline in individuals with early Alzheimer's disease, typically earlier than when other senses and thinking abilities begin to decline. Memory for new odors is particularly diminished in these individuals. Existing treatments for AD do not improve these symptoms. A targeted treatment for improving sense of smell, called 'Olfactory Training', has been used to improve sense of smell in people with various forms of smell loss, though it is not known whether it can improve smell abilities and thinking abilities in patients who are at high risk of developing Alzheimer's disease. The investigators will conduct a randomized clinical trial with patients who have mild cognitive impairment (MCI). This is an early phase of memory loss that is worse than normal aging and may precede Alzheimer's disease. Patients will be randomized to either olfactory memory training or visual memory training for 3 months, with a final follow-up visit at 6 months. This study will attempt to determine if olfactory training is a useful for improving smell abilities, thinking abilities, and everyday functioning by examining change in these outcomes over time.

Primary Outcome

The PACC5 provides a comprehensive assessment of Alzheimer's disease-relevant cognitive impairment and to serve as a tool with validated sensitivity to detect cognitive decline over time. It is comprised of five tests: Mini-Mental State Examination (total score range 0-30), Wechsler Memory Scale-Revised Logical Memory Delayed Recall (total score range 0-25), Digit-Symbol Coding Test (total score range 0-93), Free and Cued Selective Reminding Test Free + Total Recall (total score range 0-96), and

Conditions Studied

Interventions

  • BEHAVIORAL Olfactory Memory Training
  • BEHAVIORAL Visual Memory Training

Study Locations (1)

New York

  • New York State Psychiatric Institute - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2025-08-07
Est. Completion 2028-03-31
Phase NA
Jeffrey Motter

1 total trials

What NCT06825403 shows while recruiting

NCT06825403 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 2 interventions - of which Olfactory Memory Training is the first listed.

NCT06825403 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT06825403 about?

NCT06825403 is a clinical study titled "Olfactory Training in Mild Cognitive Impairment". Sense of smell tends to decline in individuals with early Alzheimer's disease, typically earlier than when other senses and thinking abilities begin to decline. Memory for new odors is particularly diminished in these individuals. Existing treatments for AD do not improve these symptoms. A targeted ...

What is the current status of trial NCT06825403?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-08-07. Estimated completion is 2028-03-31.

What conditions does trial NCT06825403 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment.

What interventions are being tested in trial NCT06825403?

The interventions under investigation include: Olfactory Memory Training (BEHAVIORAL), Visual Memory Training (BEHAVIORAL).

Who is sponsoring clinical trial NCT06825403?

This trial is sponsored by Jeffrey Motter, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06825403 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06825403's enrollment target sits among peer trials

30 166th of 205 higher than 37 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06825403, the US trial registry maintained by the National Library of Medicine. NCT06825403 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.